10 Year Prostate Stereotactic Body Radiotherapy Outcomes: Relapse-free Survival, PSA Kinetics And Toxicity From A Pooled Analysis Of Two Multi-Institutional Trials

Stereotactic body radiation therapy (SBRT) is gaining prevalence as primary therapy for localized prostate cancer, though long-term data remain sparse. We present the combined result of two prospective multi-institutional SBRT trials with mature follow-up, reporting clinical relapse-free survival, late PSA kinetics and the cumulative incidence of grade 2 or higher adverse events to 10 years. 39 institutions enrolled 569 patients - 284 low-risk...